Get the Stockscreener App
6.59
5.18%
-0.36
After Hours:
6.57
-0.02
-0.30%
Aptevo Therapeutics Inc stock is traded at $6.59, with a volume of 38,070.
It is down -5.18% in the last 24 hours and down -26.53% over the past month.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
See More
Previous Close:
$6.95
Open:
$6.94
24h Volume:
38,070
Relative Volume:
0.22
Market Cap:
$6.58M
Revenue:
$12.99M
Net Income/Loss:
$-23.72M
P/E Ratio:
-0.0678
EPS:
-97.2514
Net Cash Flow:
$-23.28M
1W Performance:
+9.65%
1M Performance:
-26.53%
6M Performance:
-82.23%
1Y Performance:
-99.51%
1-Day Range:
$6.40
$7.11
1-Week Range:
$6.06
$7.16
52-Week Range:
$5.94
$1,439.96
Aptevo Therapeutics Inc Stock (APVO) Company Profile
Name
Aptevo Therapeutics Inc
Sector
Industry
Phone
206-838-0500
Address
2401 4TH AVE., SEATTLE, WA
Compare APVO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APVO
Aptevo Therapeutics Inc
|
6.59 | 6.93M | 12.99M | -23.72M | -23.28M | -97.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-18 | Initiated | Ladenburg Thalmann | Buy |
| Oct-05-17 | Resumed | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc Stock (APVO) Latest News
Aug Rallies: What is Aptevo Therapeutics Inc. s 5 year growth outlookJuly 2025 Setups & Verified Entry Point Detection - mfd.ru
Risk Hedge: Is Aptevo Therapeutics Inc stock trending bullishPortfolio Update Summary & Growth Oriented Trading Recommendations - baoquankhu1.vn
Risk Report: Is Aptevo Therapeutics Inc impacted by rising ratesChart Signals & Safe Swing Trade Setups - baoquankhu1.vn
Aptevo Therapeutics announces leadership changes as CEO retires By Investing.com - Investing.com Canada
Aptevo Announces CEO Changes - marketscreener.com
Aptevo Therapeutics Inc. Announces Board and Executive Changes - marketscreener.com
Aptevo Therapeutics Names Jeff Lamothe President and CEO as Marvin White Becomes Executive Chair - citybiz
Is Onto Innovation Inc stock risky to hold now2025 Support & Resistance & Detailed Earnings Play Strategies - baoquankhu1.vn
Aptevo Therapeutics (APVO) Announces Changes in Leadership to Pr - GuruFocus
Aptevo Therapeutics IncMarvin White to retire as Aptevo CEO effective April 1, 2026SEC filing - marketscreener.com
Aptevo Therapeutics Announces CEO Transition and Leadership Changes - The Globe and Mail
Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth - The Globe and Mail
Aptevo Therapeutics announces leadership changes as CEO retires - Investing.com
Aptevo (NASDAQ: APVO) elevates COO Jeff Lamothe to succeed CEO Marvin White - Stock Titan
Cancer drug developer Aptevo hands CEO role to operations chief - Stock Titan
Aptevo Therapeutics (APVO) Announces Offering of 7.075 Million S - GuruFocus
Aptevo Therapeutics prospectus relates to offer and sale of up to 7,075,471 shares of our common stock by selling stockholder - marketscreener.com
Aptevo Therapeutics Prospectus Relates To Offer And Sale Of Up To 7,075,471 Shares Of Our Common Stock By Selling Stockholder - TradingView
Aug Rallies: Is Aptevo Therapeutics Inc impacted by rising ratesJuly 2025 EndofMonth & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Growth Report: Can Compass Minerals International Inc. deliver consistent EPS growthInsider Selling & Community Verified Swing Trade Signals - baoquankhu1.vn
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Take Profit: Is Weave Communications Inc a defensive stock2025 Analyst Calls & Accurate Intraday Trading Signals - baoquankhu1.vn
VIX Spike: What are Aptevo Therapeutics Incs recent SEC filings showingTrade Exit Report & Fast Moving Market Watchlists - baoquankhu1.vn
Chipmakers Recap: Is NTNX stock overvalued or fairly priced2025 Buyback Activity & Reliable Price Action Trade Plans - baoquankhu1.vn
Aptevo Therapeutics (NASDAQ: APVO) seeks OK for $60M SEPA share sales - Stock Titan
Income Plays: Does Eastman Kodak Company align with a passive investing strategy - baoquankhu1.vn
Market Overview: How sensitive is HUHUTECH International Group Inc to inflationJuly 2025 Movers & Verified Momentum Stock Watchlist - baoquankhu1.vn
Aptevo Therapeutics (APVO) Price Target Increased by 1,700.00% to 7,711.20 - Nasdaq
Aptevo Therapeutics shares jump after $60 million equity facility secured - MSN
HOKA Size Guide: What valuation multiples suggest for Aptevo Therapeutics Inc. stockNew Releases Roundup & road comfort picks for daily use - Улправда
Aptevo Therapeutics Secures $60 Million Equity Financing Facility - The Globe and Mail
Aptevo Therapeutics Inc. (APVO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Aptevo Therapeutics stock jumps after securing $60 million equity line By Investing.com - Investing.com South Africa
Aptevo Therapeutics stock jumps after securing $60 million equity line - Investing.com
Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality - The Globe and Mail
Aptevo secures $60 million equity line of credit to fund operations - Investing.com Nigeria
Aptevo Therapeutics (APVO) Secures $60 Million Equity Line - GuruFocus
Aptevo Therapeutics enters equity purchase agreement with YA II PN, Ltd - marketscreener.com
Aptevo Therapeutics Signs Standby Equity Purchase Agreement With Yorkville - TradingView — Track All Markets
Biotech lines up $60M to keep next-wave cancer drugs moving to 2029 - Stock Titan
What valuation multiples suggest for Aptevo Therapeutics Inc. stockNew Releases Roundup & road comfort picks for daily use - Улправда
Will Aptevo Therapeutics Inc. (AP81) stock maintain strong growthWeekly Stock Recap & Community Supported Trade Ideas - Улправда
Will Aptevo Therapeutics Inc. stock deliver shareholder valueEarnings Risk Report & Low Risk High Reward Trade Ideas - Улправда
Will Aptevo Therapeutics Inc. stock continue upward momentum2025 Top Decliners & Fast Momentum Entry Tips - Улправда
Is Aptevo Therapeutics Inc. stock a smart buy before Fed meetingPortfolio Performance Summary & Free Verified High Yield Trade Plans - Улправда
Quarterly Trades: What consensus target says about Aptevo Therapeutics Inc. (AP81) stockCEO Change & Risk Controlled Daily Trade Plans - Улправда
Is Aptevo Therapeutics Inc. stock a buy for dividend growthRisk Management & Technical Confirmation Trade Alerts - Улправда
Aptevo Therapeutics Inc Stock (APVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):